Esparma Pharma Services Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Esparma Pharma Services Gmbh Pharmaceutical Import Records from India — 2 Products, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Esparma Pharma Services Gmbh — Pharmaceutical Importer Profile (2026) | 2 Products, $1.2M Trade | TransData Nexus

Esparma Pharma Services Gmbh

Pharmaceutical Importer · Germany · Respiratory Focus · $1.2M Total Trade · DGFT Verified

Esparma Pharma Services Gmbh is a pharmaceutical importer based in Germany with a total trade value of $1.2M across 2 products in 2 therapeutic categories. Based on 25 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Esparma Pharma Services Gmbh sources from 14 verified Indian suppliers, with Cipla Limited accounting for 25.7% of imports.

Esparma Pharma Services Gmbh — Import Portfolio & Supplier Network

Esparma Pharma Services Gmbh import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Esparma Pharma Services Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$2.1M	230	25.7%
Alembic Pharmaceuticals Limited	$1.9M	122	22.9%
Centaur Pharmaceuticals Private Limited

What Formulations Does Esparma Pharma Services Gmbh Import?

Formulation	Value	Ships
Colecalciferol aristo 20000 IU	$298.5K	6
Venlafaxin aristo 225 MG 10x10 cap	$237.9K	5
Budes n inhaler 0.2MG (budesonide 200mcg	$217.0K	6
Budes n inhaler 0.2MG budesonide 200mcgpack	$200.0K	4
Bupropion sandoz 150MG TAB 1x90s bot	$199.6K	5
Indian harmless medicines aristo 1 MG	$163.5K	4
Colecalciferol aristo 20000 IU capsulessoft Each soft gelatin capsule cont colecalciferol ph eur 20000 IU 5x10's	$137.4K	3
Budes n inhaler 0.2MG (twin Pack)	$130.6K	3
Indian harmless medicines -	$130.5K	3
Budes n inhaler 0.2MG (triple Pack)	$130.5K	3
Pharma product:kostarox russia 90MG 1	$120.1K	3
Rosuzet 20 MG/10 MG tablets(10x10t)bl	$106.0K	4
Pharmaceutical drugs and medicine	$105.2K	4
Rosuzet 20 MG/10 MG tablets	$101.3K	4
Airflusal 25/250mcg inhalerfluticasone	$100.0K	2

Esparma Pharma Services Gmbh imports 315 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Budesonide	Respiratory	$1.1M	22	0.6%	9
2	Lorazepam	CNS & Psychiatric	$79.9K	3	3.2%	8

Esparma Pharma Services Gmbh imports 2 pharmaceutical products across 2 categories into Germany totaling $1.2M.

Esparma Pharma Services Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Esparma Pharma Services GmbH is a German pharmaceutical logistics provider specializing in the storage, order picking, and distribution of finished pharmaceutical products. Established in 2009, the company operates as a subsidiary of Aristo Pharma GmbH, which was formed in 2008 through the merger of several traditional German pharmaceutical companies with histories dating back to 1875. Aristo Pharma focuses on the production and distribution of active ingredients in the generics market, marketing them under their own brand. Esparma Pharma Services GmbH plays a pivotal role within the Aristo Pharma Group by managing the logistics operations, ensuring the efficient handling and distribution of pharmaceutical products across Germany and Europe. (esparma-pharma-services.de)

The company's headquarters are located in Osterweddingen, Germany, serving as the central logistics hub for the Aristo Pharma Group. Esparma Pharma Services GmbH is responsible for the storage, order picking, and distribution of pharmaceutical products, including prescription and over-the-counter medicines, herbal remedies, and modern medical products. With a team of approximately 120 employees, the company ensures the smooth logistics processes for the Aristo Pharma Group and various third-party customers from the healthcare industry. (esparma-pharma-services.de)

2Distribution Network

Esparma Pharma Services GmbH operates a state-of-the-art logistics center in Osterweddingen, Germany, encompassing 36,500 square meters of pharmaceutical storage space. This facility is equipped to store pharmaceuticals, medical products, food supplements, and cosmetic products, with over 35,000 pallet spaces available. The company offers storage in ambient (15 to 25 degrees Celsius) and refrigerated (2 to 8 degrees Celsius) ranges, as well as specialized storage for narcotics in compliance with legal requirements. Additionally, Esparma Pharma Services GmbH provides packaging services, including serialization, replacement of package inserts, size repackaging, and sample production. (esparma-pharma-services.de)

The logistics center serves as the distribution hub for the Aristo Pharma Group and various third-party customers, ensuring efficient order processing and timely delivery across Germany and neighboring European countries. The company's commitment to modernizing and expanding its facilities enables it to meet the growing demands of the pharmaceutical market, providing flexible and future-proof solutions. (esparma-pharma-services.de)

3Industry Role

Esparma Pharma Services GmbH functions primarily as a logistics intermediary within Germany's pharmaceutical supply chain. While it does not engage in the manufacturing or direct wholesale distribution of pharmaceutical products, it plays a crucial role in the efficient storage, order picking, and distribution of finished pharmaceutical goods. By managing these logistics operations, Esparma Pharma Services GmbH ensures that pharmaceutical products reach their intended destinations promptly and in optimal condition, supporting the broader supply chain activities of the Aristo Pharma Group and its third-party clients. (esparma-pharma-services.de)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Esparma Pharma Services Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Esparma Pharma Services GmbH's sourcing strategy reveals a significant concentration in its supplier base, particularly from India. The company's total import value from India amounts to $1.2 million USD, distributed across 25 shipments. The top five products imported from India include Budesonide ($1.1 million, Rank #9, 0.6% share) and Lorazepam ($80K, Rank #8, 3.2% share). These two products alone constitute a substantial portion of the company's imports, indicating a high level of dependency on these specific suppliers and products.

This sourcing concentration suggests that Esparma Pharma Services GmbH may face risks associated with single-source dependency, such as supply disruptions or price volatility. However, the company's diversified supplier base, with 14 unique Indian suppliers, may mitigate some of these risks. The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent number of shipments over the years. Nonetheless, the heavy reliance on a limited number of products and suppliers could impact the company's ability to adapt to market changes or supply chain disruptions.

2Supply Chain Resilience

Esparma Pharma Services GmbH's supply chain resilience is influenced by its sourcing strategy from India. The company's reliance on a select group of Indian suppliers for its top products indicates a potential vulnerability to supply chain disruptions. While the diversified supplier base may offer some flexibility, the concentration in specific products and suppliers could pose challenges in maintaining a consistent supply of finished pharmaceutical formulations.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the primary regulatory authority overseeing pharmaceutical imports is the Federal Institute for Drugs and Medical Devices (BfArM). The key legislation governing pharmaceutical imports includes the German Medicines Act (AMG) and the Ordinance on the Wholesale Distribution of Medicinal Products (AM-HandelsV). These regulations ensure that imported pharmaceutical products meet the required quality, safety, and efficacy standards before they enter the German market.

The marketing authorization pathway for Indian generics involves obtaining approval from BfArM, which assesses the quality, safety, and efficacy of the products. Additionally, compliance with Good Manufacturing Practice (GMP) standards, recognized by the European Medicines Agency (EMA), is mandatory for all pharmaceutical imports. This ensures that imported generics adhere to the stringent manufacturing standards required in Germany.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Germany necessitate that importers hold a valid wholesale distribution authorization issued by BfArM. This authorization ensures that importers comply with the necessary regulatory standards for handling and distributing medicinal products. Furthermore, imported pharmaceutical products must be accompanied by a GMP certificate, which can be recognized from EU GMP, WHO GMP, or PIC/S standards. This certification attests to the adherence of manufacturing processes to internationally recognized quality standards.

Esparma Pharma Services Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Esparma Pharma Services GmbH's product category focus on respiratory and CNS & psychiatric medications aligns with market demand for these therapeutic areas. The substantial import value of Budesonide ($1.1 million) and Lorazepam ($80K) indicates a strategic emphasis on these products. The high import value of Budesonide suggests a significant market demand for respiratory treatments, while the import of Lorazepam reflects a need for CNS & psychiatric medications. This focus enables Esparma Pharma Services GmbH to cater to critical healthcare needs within Germany and Europe.

2Sourcing Profile

Esparma Pharma Services GmbH's sourcing strategy involves importing finished pharmaceutical formulations from India, with a particular emphasis on respiratory and CNS & psychiatric medications. The company's reliance on a select group of Indian suppliers for these products indicates a strategic choice to leverage India's manufacturing capabilities and cost advantages. By focusing on finished formulations, Esparma Pharma Services GmbH ensures that imported products are ready for distribution, streamlining the supply chain and meeting the immediate needs of the German market.

3Market Positioning

Frequently Asked Questions — Esparma Pharma Services Gmbh

What products does Esparma Pharma Services Gmbh import from India?

Esparma Pharma Services Gmbh imports 2 pharmaceutical products across 2 categories. Top imports: Budesonide ($1.1M), Lorazepam ($79.9K).

Who supplies pharmaceuticals to Esparma Pharma Services Gmbh from India?

Esparma Pharma Services Gmbh sources from 14 verified Indian suppliers. The primary supplier is Cipla Limited (25.7% of imports, $2.1M).

What is Esparma Pharma Services Gmbh's total pharmaceutical import value?

Esparma Pharma Services Gmbh's total pharmaceutical import value from India is $1.2M, based on 25 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Esparma Pharma Services Gmbh focus on?

Esparma Pharma Services Gmbh imports across 2 categories. The largest: Respiratory (93.2%), CNS & Psychiatric (6.8%).

Get Full Esparma Pharma Services Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.